Caribou Biosciences Inc. (NASDAQ: CRBU) stock jumped 0.94% on Monday to $6.45 against a previous-day closing price of $6.39. With 0.54 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.47 whereas the lowest price it dropped to was $6.22. The 52-week range on CRBU shows that it touched its highest point at $13.19 and its lowest point at $4.89 during that stretch. It currently has a 1-year price target of $29.14.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRBU was down-trending over the past week, with a drop of -10.66%, but this was down by -2.86% over a month. Three-month performance dropped to -28.25% while six-month performance fell -14.57%. The stock lost -39.94% in the past year, while it has gained 2.71% so far this year. A look at the trailing 12-month EPS for CRBU yields -1.50 with Next year EPS estimates of -1.96. For the next quarter, that number is -0.46. This implies an EPS growth rate of -83.60% for this year and -16.00% for next year.
Float and Shares Shorts:
At present, 60.89 million CRBU shares are outstanding with a float of 54.41 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.97 million, which was 6.53% higher than short shares on Sep 14, 2022. In addition to Dr. Rachel E. Haurwitz Ph.D. as the firm’s Co-Founder, CEO, Pres & Director, Mr. Jason V. O’Byrne M.B.A. serves as its Chief Financial Officer.
Through their ownership of 62.51% of CRBU’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 7.01% of CRBU, in contrast to 45.62% held by mutual funds. Shares owned by individuals account for 27.04%. As the largest shareholder in CRBU with 9.84% of the stake, PFM Health Sciences LP holds 6,000,000 shares worth 6,000,000. A second-largest stockholder of CRBU, BlackRock Fund Advisors, holds 3,819,189 shares, controlling over 6.26% of the firm’s shares. Pictet Asset Management SA is the third largest shareholder in CRBU, holding 3,290,898 shares or 5.40% stake. With a 3.40% stake in CRBU, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,073,214 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.43% of CRBU stock, is the second-largest Mutual Fund holder. It holds 1,479,875 shares valued at 9.29 million. Pictet – Biotech holds 2.38% of the stake in CRBU, owning 1,451,388 shares worth 9.11 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRBU since 7 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRBU analysts setting a high price target of $37.00 and a low target of $19.00, the average target price over the next 12 months is $29.14. Based on these targets, CRBU could surge 473.64% to reach the target high and rise by 194.57% to reach the target low. Reaching the average price target will result in a growth of 351.78% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CRBU will report FY 2022 earnings on 03/19/2024. Analysts have provided yearly estimates in a range of -$1.63 being high and -$1.80 being low. For CRBU, this leads to a yearly average estimate of -$1.69. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Caribou Biosciences Inc. surprised analysts by $0.04 when it reported -$0.44 EPS against a consensus estimate of -$0.48. The surprise factor in the prior quarter was -$0.08. Based on analyst estimates, the high estimate for the next quarter is -$0.40 and the low estimate is -$0.54. The average estimate for the next quarter is thus -$0.46.
Summary of Insider Activity:
Insiders traded CRBU stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 21,401 shares were bought while 0 shares were sold. The number of buy transactions has increased to 20 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 306,794 while 53,248 shares were sold.